Peptides of cardiac origin, termed atrial natriuretic factors, possess both natriuretic and diuretic properties, actions which physiologically contradict those of the antidiuretic peptide, arginine vasopressin (AVP). In addition to their opposing actions in the kidney, the present results indicate that one of these factors, Atriopeptin III, can inhibit dehydration and hemorrhage-induced AVP release in the rat. 3 days of water deprivation resulted in elevated plasma AVP levels (36.1 ± 4.7 pg AVP/ml) which were significantly reduced following intravenous infusion of 0.02 (21.4 + 3.6), 0.2 (15.6 ± 1.6), and 2.0 (13.9 ± 3.8) nmol Atriopeptin III. Furthermore, 2.0 nmol Atriopeptin III significantly reduced post-hemorrhage levels (54.8 ± 13.7) of AVP to values that approximated resting levels (10.2 ± 3.7). The results suggest a role for cardiac peptides in the control of AVP release as well as the existence of a counterregulatory system, peptidergic in nature, for the maintenance of fluid and electrolyte homeostasis.

Keywords:
Atrial natriuretic factor, Vasopressin, Hemorrhage, Dehydration
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.